PW Medtech GroupFRA:PWE 82 Net Margin % is 6.94% as of Dec. 2025, which is 79% below its 10-year median of 32.62. GuruFocus rates FRA:PWE with a GF Score™ of 82/100 and a GF Value™ of €0.13. The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, PW Medtech Group ranks better than 76.74% on this metric.
The historical rank and industry rank for PW Medtech Group's Net Margin % or its related term are showing as below:
FRA:PWE'
s Net Margin % Range Over the Past 10 Years
Min: 11.44 Med: 32.62 Max: 535.89
Current: 11.44
FRA:PWE's Net Margin % is ranked better than 76.74% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:PWE: 11.44
PW Medtech Group (FRA:PWE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PW Medtech Group Net Margin % Related Terms
PW Medtech Group Net Margin % Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PWE vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PW Medtech Group (FRA:PWE) has a Net Margin % of 6.94% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on PW Medtech Group and its competitors. This is 79% below median its historical median of 32.62. Over the past decade, PW Medtech Group's Net Margin % has ranged from 11.44 to 535.89. According to the industry distribution chart, PW Medtech Group ranks #190 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 23.3%.
Is PW Medtech Group's Net Margin % too high?
PW Medtech Group's current Net Margin % of 6.94% is 79% below median its 10-year median of 32.62. Over the past 10 years, this metric has ranged from a low of 11.44 to a high of 535.89. The Medical Devices & Instruments industry median Net Margin % is 2.07. PW Medtech Group's value of 6.94% is 235.3% above this industry median. Based on the distribution chart, PW Medtech Group ranks #190 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PW Medtech Group has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #190 out of 817 companies for Net Margin %. This places PW Medtech Group in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. PW Medtech Group's value of 6.94% is 235.3% above this benchmark. Historically, PW Medtech Group's own Net Margin % has ranged from 11.44 to 535.89 over the past decade. While the company's 10-year median is 32.62 vs. the industry median of 2.07, PW Medtech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current Net Margin % of 6.94% is 235.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current Net Margin % is 6.94%, which is 79% below median its own 10-year median of 32.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current Net Margin % of 6.94%. The stock's GF Value™ is €0.13, compared to a current price of €0.11 — trading 13.8% below its estimated fair value. The current Net Margin % is 6.94%, which is 79% below median its 10-year median of 32.62 and 235.3% above the Medical Devices & Instruments industry median of 2.07. PW Medtech Group's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Net Margin % is 6.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.11 is trading 13.8% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:PWE:
Net Margin %: 6.94% (79% below median its 10-year median of 32.62)
GF Value™: €0.13 vs. price of €0.11 (13.8% below fair value)
Industry Position: 235.3% above the Medical Devices & Instruments median (#190 of 817)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
82GF Score
Get the complete analysis for FRA:PWE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
